PHARMACEUTICAL COMPOSITIONS AND ORAL ORAL DOSED FORMS OF LEVERODOPE'S MEDICINAL PRODUCTS AND METHODS OF APPLICATION

摘要

1. A pharmaceutical composition comprising: crystalline (2) -2-phenylcarbonyloxypropyl (2) -2-amino-3- (3,4-dihydroxyphenyl) propanoate mesylate; and alkyl sulfate or a pharmaceutically acceptable salt thereof. 2. The pharmaceutical composition according to claim 1, containing granules, where the granules contain: from about 90 wt.% To about 99 wt.% Crystalline (2) -2-phenylcarbonyloxypropyl (2) -2-amino-3- (3,4-dihydroxyphenyl ) mesylate propanoate; iota from about 0.5 wt.% to about 2 wt.% Calkyl sulfate or its pharmaceutically acceptable sa where wt.% is calculated from the total dry matter of the granules. 3. The pharmaceutical composition of claim 2, wherein the C1-6 alkyl sulfate or a pharmaceutically acceptable salt thereof is sodium lauryl sulfate. The pharmaceutical composition according to claim 1, containing one or more pharmaceutically acceptable excipients. The pharmaceutical composition according to claim 1, comprising: from about 50 wt.% To about 90 wt.% Crystalline (2) -2-phenylcarbonyloxypropyl (2) -2-amino-3- (3,4-dihydroxyphenyl) propanoate mesylate; from about 0.5% to about 2.0% by weight of a C 1-6 alkyl sulfate or a pharmaceutically acceptable salt thereof; from about 6% to about 20% by weight hydroxypropyl methylcellulose; and from about 0.5 wt.% to about 2.0 wt.% magnesium stearate, where wt.% is calculated from the total dry weight of the composition. The pharmaceutical composition according to claim 1, comprising an L-aromatic amino acid decarboxylase inhibitor, a catechol methyltransferase inhibitor, or a combination of an L-aromatic amino acid decarboxylase inhibitor and a catechol inhibitor methyltransferase. Oral dose